BRACKEMEYER, PAUL J.,GARRETT, COLLEEN C.,NORDSTROEM, LARS FREDRIK,SHEIKH, AHMAD Y.,ZHANG, GEOFF G.,ZHU, DONGHUA
申请号：
CA3022292
公开号：
CA3022292A1
申请日:
2017.04.25
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present invention features crystalline polymorphs of dimethyl (2S, 2S)-1,1, -((2S,2S)-2, 2, -(4, 4, -((2S,5S)-1- (4-tert- butylphenyl) pyrrolidine-2,5-diyl) bis (4, l-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,l-diyl)) bis (3-methyl-l- oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of Figures 1-11.
